...
首页> 外文期刊>Trials >A trial to determine whether septic shock-reversal is quicker in pediatric patients randomized to an early goal-directed fluid-sparing strategy versus usual care (SQUEEZE): study protocol for a pilot randomized controlled trial
【24h】

A trial to determine whether septic shock-reversal is quicker in pediatric patients randomized to an early goal-directed fluid-sparing strategy versus usual care (SQUEEZE): study protocol for a pilot randomized controlled trial

机译:一项确定小儿患者败血性休克逆转是否更快的试验,该患者被随机分配到早期目标导向的积液策略与常规护理(SQUEEZE):一项试验性随机对照试验的研究方案

获取原文
           

摘要

Background Current pediatric septic shock resuscitation guidelines from the American College of Critical Care Medicine focus on the early and goal-directed administration of intravascular fluid followed by vasoactive medication infusions for persistent and fluid-refractory shock. However, accumulating adult and pediatric data suggest that excessive fluid administration is associated with worse patient outcomes and even increased risk of death. The optimal amount of intravascular fluid required in early pediatric septic shock resuscitation prior to the initiation of vasoactive support remains unanswered. Methods/design The SQUEEZE Pilot Trial is a pragmatic, two-arm, parallel-group, open-label, prospective pilot randomized controlled trial. Participants are children aged 29?days to under?18 years with suspected or confirmed septic shock and a need for ongoing resuscitation. Eligible participants are enrolled under an exception to consent process and randomly assigned via concealed allocation to either the Usual Care (control) or Fluid Sparing (intervention) resuscitation strategy. The primary objective of this pilot trial is to determine feasibility, based on the ability to enroll participants and to adhere to the study protocol. The primary outcome measure by which success will be determined is participant enrollment rate ("pass" defined as at least two participants/site/month, recognizing that enrollment may be slower during the run-in phase). Secondary objectives include assessing (1) appropriateness of eligibility criteria, and (2) completeness of clinical outcomes to inform the endpoints for the planned multisite trial. To support the nested translational study, SQUEEZE-D, we will also evaluate the feasibility of describing cell-free DNA (a procoagulant molecule with prognostic utility) in blood samples obtained from children enrolled into the SQUEEZE Pilot Trial at baseline and at 24?h. Discussion The optimal degree of fluid resuscitation and the timing of initiation of vasoactive support in order to achieve recommended therapeutic targets in children with septic shock remains unanswered. No prospective study to date has examined this important question for children in developed countries including Canada. Recruitment for the SQUEEZE Pilot Trial opened on 6 January 2014. Findings will inform the feasibility of the planned multicenter trial to answer our overall research question. Trial registration ClinicalTrials.gov Identifier NCT01973907 , registered on 23 October 2013.
机译:背景技术美国重症医学学院目前的小儿败血性休克复苏指南着重于对血管内液体的早期和目标导向给药,然后进行持续性和难治性休克的血管活性药物输注。但是,不断积累的成人和儿科数据表明,过量输液与患者预后不良甚至死亡风险增加有关。在开始血管活性支持之前,早期小儿败血性休克复苏所需的最佳血管内液量仍未得到解答。方法/设计SQUEEZE飞行员试验是一项实用,两臂,平行组,开放标签,前瞻性飞行员随机对照试验。参与者为29天至18岁以下的儿童,他们怀疑或证实患有败血性休克,需要进行持续的复苏。符合条件的参与者按照同意流程的例外进行注册,并通过隐性分配随机分配到“常规护理”(对照)或“节约液体”(干预)复苏策略。该试验性试验的主要目的是根据招募参加者和遵守研究方案的能力来确定可行性。决定成功的主要结果指标是参与者的入学率(“合格”定义为至少两个参与者/站点/月,因为他们认为进入阶段可能会慢一些)。次要目标包括评估(1)资格标准的适当性,以及(2)临床结果的完整性,以告知计划中的多站点试验的终点。为支持嵌套翻译研究SQUEEZE-D,我们还将评估在基线和24?h加入SQUEEZE Pilot Trial的儿童血液样本中描述无细胞DNA(具有预后功能的促凝分子)的可行性。 。讨论为达到感染性休克儿童的推荐治疗目标,最佳的液体复苏程度和开始血管活性支持的时机尚未得到解答。迄今为止,尚无前瞻性研究针对包括加拿大在内的发达国家的儿童研究这一重要问题。 SQUEEZE试点研究的招募工作于2014年1月6日开始。调查结果将告知计划的多中心试验的可行性,以回答我们的总体研究问题。试用注册ClinicalTrials.gov标识符NCT01973907,于2013年10月23日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号